Cargando…

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma

Oncolytic viruses can target neoplasms, triggering oncolytic and immune effects. Their delivery to melanoma lesions remains challenging. Bone-marrow-derived mesenchymal stem cells (MSCs) were shown to be permissive for oncolytic myxoma virus (MYXV), allowing its transfer to melanoma cells, leading t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jazowiecka-Rakus, Joanna, Sochanik, Aleksander, Rusin, Aleksandra, Hadryś, Agata, Fidyk, Wojciech, Villa, Nancy, Rahman, Masmudur M., Chmielik, Ewa, Franco, Lina S., McFadden, Grant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398944/ https://www.ncbi.nlm.nih.gov/pubmed/32775618 http://dx.doi.org/10.1016/j.omto.2020.07.003

Ejemplares similares

Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2022)

Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2021)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021)

NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy
por: Cornejo, Yvonne, et al.
Publicado: (2020)

The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase
por: Woo, Yanghee, et al.
Publicado: (2021)

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
por: Rahman, Masmudur M., et al.
Publicado: (2020)

RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
por: Rahman, Masmudur M., et al.
Publicado: (2023)

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
por: Lilly, Cameron L., et al.
Publicado: (2016)

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma
por: Villa, Nancy.Y., et al.
Publicado: (2020)

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
por: Phelps, Michael P., et al.
Publicado: (2018)

Co-Regulation of NF-κB and Inflammasome-Mediated Inflammatory Responses by Myxoma Virus Pyrin Domain-Containing Protein M013
por: Rahman, Masmudur M., et al.
Publicado: (2009)

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma
por: Villa, Nancy Y., et al.
Publicado: (2022)

Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication
por: Rahman, Masmudur M., et al.
Publicado: (2013)

Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma
por: Christie, John D., et al.
Publicado: (2022)

Modulation of Tumor Necrosis Factor by Microbial Pathogens
por: Rahman, Masmudur M, et al.
Publicado: (2006)

Modulation of NF-κB signalling by microbial pathogens
por: Rahman, Masmudur M., et al.
Publicado: (2011)

Role of cytokines in poxvirus host tropism and adaptation
por: Rahman, Masmudur M, et al.
Publicado: (2022)

Oncolytic Viruses and the Immune System: The Dynamic Duo
por: Lemos de Matos, Ana, et al.
Publicado: (2020)

Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo
por: Weng, Mingzhe, et al.
Publicado: (2014)

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
por: Villa, Nancy Y., et al.
Publicado: (2016)

Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells
por: Kim, Manbok, et al.
Publicado: (2009)

Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma
por: Christie, John D., et al.
Publicado: (2021)

Myxoma Virus Infection Promotes NK Lysis of Malignant Gliomas In Vitro and In Vivo
por: Ogbomo, Henry, et al.
Publicado: (2013)

RIG-I Mediates the Co-Induction of Tumor Necrosis Factor and Type I Interferon Elicited by Myxoma Virus in Primary Human Macrophages
por: Wang, Fuan, et al.
Publicado: (2008)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Resistance to Oncolytic Myxoma Virus Therapy in Nf1(−/−)/Trp53(−/−) Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon
por: Zemp, Franz J., et al.
Publicado: (2013)

Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses
por: Everts, Anne, et al.
Publicado: (2020)

Cytokine determinants of viral tropism
por: McFadden, Grant, et al.
Publicado: (2009)

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy
por: Enow, Junior A., et al.
Publicado: (2023)

The current status and future directions of myxoma virus, a master in immune evasion
por: Spiesschaert, Bart, et al.
Publicado: (2011)

Metabolic signatures associated with oncolytic myxoma viral infections
por: Mahar, Rohit, et al.
Publicado: (2022)

Identification of a Novel Myxoma Virus C7-Like Host Range Factor That Enabled a Species Leap from Rabbits to Hares
por: Águeda-Pinto, Ana, et al.
Publicado: (2022)

Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection
por: Thomas, Raquela J., et al.
Publicado: (2023)

Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
por: MacNeill, Amy L., et al.
Publicado: (2018)

Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
por: Burton, Chase, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ttbjdbv7rlsq3utg580p49be99